A NSW Government website

On

Tissue Pathology and Diagnostic Oncology Research

Tissue Pathology and Diagnostic Oncology at RPA has a broad-based research program encompassing basic, translational and clinical studies in a wide range of organs, including skin, head and neck, lung, breast, colorectum, prostate, liver and pancreas. 

The melanoma group studies causes, diagnosis, prognostication and treatment in one of Australia's most common malignancies and are recognised international leaders in this field. The head and neck, lung, prostate and breast groups have established national and international profiles in pathology research focusing on diagnosis and prediction of behaviour in these tumours, as well as developing predictive markers for targeted therapy. 

Man wearing a white lab coat using a computer
SydneyConnect Image: Researcher Professor Richard Scolyer AO

Selected Grants

Amount awarded Grant and project details
$7,000,000 Medical Research Future Fund (MRFF), 2021-2026
Cartilage based stem cell therapies for joint deformity and facial disfigurement. A framework for point of care manufacturing and delivery (ARISTOCRAT). 
Investigators: Chung P, Clark J, Mukherjee P, Gupta R
$3,937,110 NHMRC Investigator Grant, 2023-2027
Melanoma: Getting the Diagnosis and Treatment Right for Better Patient Outcomes. 
Investigator: Scolyer R (CIA)
$3,750,000  Cancer Institute NSW, 2021-2025
Improving Outcomes in Head and Neck Cancer
Investigators: Clark JR, Gupta R, Ashford BA, Ranson M, Boyer MB, Lee J, Rizos H
$3,748,551 Cancer Institute NSW Translational Program Grant, 2022-2026
Personalised Immunotherapy Program - Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform.
Investigators: Wilmott J, Long G, Scolyer RA, Boyer M, Lo S, Menzies A, Morton R, Cooper W, Gide T, Cust A. 
$3,230,670 Medical Research Future Fund (MRFF) -  International Clinical Trial Collaborations Grant Program RC Ideas Grant, 2020-2025
Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION)
Investigators: Sandhu S, Dawson S-J, Long GV, Carlino M, Menzies A, Scolyer RA, Rizos H, Lorigan P, Atkinson V, Henderson M. 
$3,217,920 NHMRC Clinical Trials and Cohort Studies Grant, 2021-2026
Reconceiving early detection of melanoma
Investigators: Mar V, Janda M, Soyer P, Penas PF, Cust A, Morton R, Wolfe R, Scolyer R, Ge Z, Lawn C. 
$2,500,000 NHMRC Centres of Research Excellence, 2021-2025
Centre of Excellence in Skin Imaging and Precision Diagnosis
Investigators: Janda M, Soyer HP, Mar V, Fernandez-Penas P, Morton R, Cust A, Wolfe R, Scolyer RA, Caffery L, Ge Z.
$2,023,376 Medical Research Future Fund (MRFF) - Efficient Use of Existing Medicines Grant,2021-2025
NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab
Investigators: Long G, Scolyer RA, McArthur G, Menzies A, Spillane A, Carlino M, Gyorki D, Saw R, Lo S, Morton RL.

Our Publications

2024

Ni Y, Watts CG, Scolyer RA, Madronio C, Armstrong BK, Morton RL, Menzies SW, Mann GJ, Thompson JF, Cust AE, Lo SN. Prognosis for people with multiple primary melanomas compared with a single primary melanoma. J Am Acad Dermatol. 2024 Jan;90(1):170-174. doi:10.1016/j.jaad.2023.08.089. Epub 2023 Sep 13.
Lo SN, Varey AHR, El Sharouni MA, Scolyer RA, Thompson JF. Online tools for predicting melanoma survival: Including sentinel node status as a variable improves prediction accuracy. J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e182-e184. doi: 10.1111/jdv.19524. Epub 2023 Oct 14.
de Almeida JR, Su JS, Kolarski MM, Truong T, Weinreb I, Perez-Ordonez B, Smith SM, Hosni A, Patel S, Valero C, Xu B, Ghossein R, Katabi N, Clark J, Low TH, Gupta R, Graboyes EM, Davies J, Richardson M, Pasham V, Jester R, Goldstein DP, Huang SH, Xu W, O'Sullivan B. Development and validation of a novel TNM staging N-classification of oral cavity squamous cell carcinoma. Cancer. 2024 Feb 1;130(3):410-420. doi: 10.1002/cncr.35020. Epub 2023 Sep 26.
Long GV, Durante J, Browne M, Scolyer RA. Affecting change as a clinical academic. Trends Cancer. 2024 Feb;10(2):93-96. doi: 10.1016/j.trecan.2023.10.003. Epub 2023 Nov 10.
Gjorup CA, Woodford R, Li I, Carlino MS, Ch'ng S, Chung D, Hsiao E, Lo SN, London K, Long GV, Menzies AM, Nieweg OE, Pennington TE, Rtshiladze MA, Saw RPM, Scolyer RA, Shannon KF, Spillane AJ, Stretch JR, Thompson JF, Varey AHR, van Akkooi ACJ. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging. Ann Surg Oncol. 2024 Mar;31(3):1857-1864. doi: 10.1245/s10434-023-14526-9. Epub 2023 Nov 15.
Lo SN, Varey AHR, El Sharouni MA, Scolyer RA, Thompson JF. Knowledge of sentinel lymph node status improves accuracy when predicting melanoma mortality and selecting patients for adjuvant immunotherapy. J Eur Acad Dermatol Venereol. 2024 Jul;38(7):e638-e639. doi: 10.1111/jdv.19709. Epub 2023 Dec 26. 
Rogiers A, Dimitriou F, Lobon I, Harvey C, Vergara IA, Pires da Silva I, Lo SN, Scolyer RA, Carlino MS, Menzies AM, Long GV. Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. Eur J Cancer. 2024 Feb;198:113506. doi:10.1016/j.ejca.2023.113506. Epub 2023 Dec 26. 
Olofsson Bagge R, Mikiver R, Marchetti MA, Lo SN, van Akkooi ACJ, Coit DG, Ingvar C, Isaksson K, Scolyer RA, Thompson JF, Varey AHR, Wong SL, Lyth J, Bartlett EK. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. JAMA Surg. 2024 Mar 1;159(3):260-268. doi: 10.1001/jamasurg.2023.6904. Erratum in: JAMA Surg. 2024 Mar 1;159(3):353. doi: 10.1001/jamasurg.2024.0338.
Bawden EG, Wagner T, Schröder J, Effern M, Hinze D, Newland L, Attrill GH, Lee AR, Engel S, Freestone D, de Lima Moreira M, Gressier E, McBain N, Bachem A, Haque A, Dong R, Ferguson AL, Edwards JJ, Ferguson PM, Scolyer RA, Wilmott JS,
Jewell CM, Brooks AG, Gyorki DE, Palendira U, Bedoui S, Waithman J, Hochheiser K, Hölzel M, Gebhardt T. CD4+T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. Sci Immunol. 2024 Jan 19;9(91):eadi9517. doi: 10.1126/sciimmunol.adi9517. Epub 2024 Jan 19.
Maher NG, Vergara IA, Long GV, Scolyer RA. Prognostic and predictive biomarkers in melanoma. Pathology. 2024 Mar;56(2):259-273. doi: 10.1016/j.pathol.2023.11.004. Epub 2023 Dec 20.
Noor A, Mair MD, Gupta R, Elliott MS, Wykes J, Palme CE, Clark JR, Low TH. When should patients with T1N0 oral squamous cell carcinoma be considered for elective neck dissection? ANZ J Surg. 2024 May;94(5):854-860. doi: 10.1111/ans.18884. Epub 2024 Jan 30. 
Varey AHR, Li I, El Sharouni MA, Simon J, Dedeilia A, Ch'ng S, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Rtshiladze M, Stretch JR, Nieweg OE, van Akkooi A, Sullivan RJ, Boland GM, Gershenwald JE, van Diest PJ, Scolyer RA, Long GV, Thompson JF, Lo SN. Predicting Recurrence-Free   and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. J Clin Oncol. 2024 Apr 1;42(10):1169-1180. doi: 10.1200/JCO.23.01020. Epub 2024 Feb 5. 
Maul LV, Jamiolkowski D, Lapides RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi ÁJ, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider E. Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. JAMA Netw Open. 2024 Feb 5;7(2):e2356479. doi:10.1001/jamanetworkopen.2023.56479. 
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Pembrolizumab versus placebo as adjuvant   therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. 
Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam KJ, de La Fouchardière A, Duncan LM, Elder DE, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Mihic-Probst D, Parker DC, Scolyer RA, Shea CR, Zembowicz A, Yun SJ, Blokx WAM, Barnhill RL. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms. Am J Surg Pathol. 2024 May 1;48(5):538-545. doi: 10.1097/PAS.0000000000002194. Epub 2024 Mar 25. 
Stassen RC, Maas CCHM, van der Veldt AAM, Lo SN, Saw RPM, Varey AHR, Scolyer RA, Long GV, Thompson JF, Rutkowski P, Keilholz U, van Akkooi ACJ, Verhoef C, van Klaveren D, Grünhagen DJ. Development and validation of a novel model to
predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Lancet Oncol. 2024 Apr;25(4):509-517. doi:10.1016/S1470-2045(24)00076-7.
Bai X, Attrill GH, Gide TN, Ferguson PM, Nahar KJ, Shang P, Vergara IA, Palendira U, da Silva IP, Carlino MS, Menzies AM, Long GV, Scolyer RA, Wilmott JS, Quek C. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma. Nat Commun. 2024 Apr 8;15(1):3014. doi: 10.1038/s41467-024-47301-9. 
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill RL, Blokx WAM, Bosenberg M, Busam KJ, de La Fouchardière A, Duncan LM, Elder DE, Ko JS, Landman G, Lazar AJ, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker DC, Redpath M, Scolyer RA, Shea CR, Spatz A, Tron V, Xu X, Yeh I, Jung Yun S, Zembowicz A, Gerami P. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms. Am J Surg Pathol. 2024 Jun 1;48(6):708-718. doi: 10.1097/PAS.0000000000002226. Epub 2024 Apr 9.
Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WAM, van Houdt W, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, Akkooi ACJV, Blank CU. Interferon-gamma signature
as prognostic and predictive marker in macroscopic stage III melanoma. J Immunother Cancer. 2024 Apr 27;12(4):e008125. doi: 10.1136/jitc-2023-008125.
Menzies AM, Lo SN, Saw RPM, Gonzalez M, Ch'ng S, Nieweg OE, Shannon KF, Ferguson PM, Lee J, Emmett L, Kapoor R, Rawson RV, Stretch JR, Thompson JF, Spillane AJ, Rizos H, Scolyer RA, Long GV. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Ann Oncol. 2024 Aug;35(8):739-746. doi: 10.1016/j.annonc.2024.05.002. Epub 2024 May 14. 
Zijlker LP, Chen H, Spillane AJ, Gonzalez M, Pennington TE, Menzies AM, Lo SN, Ferguson P, Rawson R, Colebatch AJ, Stretch JR, Thompson JF, Ch'ng S, Nieweg O, Shannon KF, Long GV, Scolyer RA, Saw RPM, van Akkooi ACJ. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort. Ann Surg Oncol. 2024 Aug;31(8):5324-5330. doi: 10.1245/s10434-024-15274-0. Epub 2024 May 18. 
Winder AA, Boyer Z, Ch'ng S, Stretch JR, Saw RPM, Shannon KF, Pennington TE, Nieweg OE, Varey AHR, Scolyer RA, Thompson JF, Cust AE, Lo SN, Spillane AJ, Smith AL. Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas. Ann Surg Oncol. 2024 Aug;31(8):5331-5339. doi: 10.1245/s10434-024-15456-w. Epub 2024 May 27. 
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2.
Pinkham MB, Herschtal A, Hong AM, Chua MS, Scolyer RA, Cumming S, Pullar A, Nobes J, Barker CA, Guadagnolo BA, Fogarty GB, Burmeister BH, Foote MC. Randomized Trial of Postoperative Radiation Therapy After Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2 Trial 01.09). Ann Surg Oncol. 2024 Sep;31(9):6088-6096. doi: 10.1245/s10434-024-15569-2. Epub 2024 Jun 8. 
Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J, Ch'ng S, Gonzalez M, Saw RPM, Pennington TE, Lo SN, Scolyer RA, Menzies AM. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF<sup>V600</sup>-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med. 2024 Sep;30(9):2540-2548. doi:10.1038/s41591-024-03077-5. Epub 2024 Jun 21. 
Pinkham MB, Herschtal A, Hong AM, Chua MS, Scolyer RA, Cumming S, Pullar A, Nobes J, Barker CA, Guadagnolo BA, Fogarty GB, Burmeister BH, Foote MC. ASO Author Reflections: The Role of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck: Now and into the Future. Ann Surg Oncol. 2024 Sep;31(9):6118-6119. doi: 10.1245/s10434-024-15657-3. Epub 2024 Jun 24. 
Li JJ, Wu XJ, Farzin M, Bray V, Williamson J, Pal A, Yip PY, Hagelamin A, Ding P, Nindra U, Vinod S, French B, Chua W, Gupta R, Cooper WA, Wang B, Lee CS. The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma. Pathology. 2024 Oct;56(6):786-794. doi: 10.1016/j.pathol.2024.04.002. Epub 2024 Jun 4. 
Quek C, Pratapa A, Bai X, Al-Eryani G, Pires da Silva I, Mayer A, Bartonicek N, Harvey K, Maher NG, Conway JW, Kasalo RJ, Ben Cheikh B, Braubach O, Palendira U, Saw RPM, Stretch JR, Shannon KF, Menzies AM, Scolyer RA, Long GV, Swarbrick A, Wilmott JS. Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Rep. 2024 Jul 23;43(7):114392. doi: 10.1016/j.celrep.2024.114392. Epub 2024 Jun 29.
Wu M, Maher N, Scolyer RA, Menzies AM, Pennington TE. Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: a very rare occurrence and literature review. Pathology. 2024 Dec;56(7):1055-1059. doi: 10.1016/j.pathol.2024.05.004. Epub 2024 Jul 15. 
Sturm RA, Smit DJ, Duffy DL, McLean C, Scolyer RA, McArthur GA, Papenfuss AT, Stark MS, Soyer HP, Mar VJ. Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma. Br J Dermatol. 2024 Dec 23;192(1):55-62. doi: 10.1093/bjd/ljae336.
Chan WY, Lee JH, Stewart A, Diefenbach RJ, Gonzalez M, Menzies AM, Blank C, Scolyer RA, Long GV, Rizos H. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy. J Exp Clin Cancer Res. 2024 Aug 21;43(1):238. doi: 10.1186/s13046-024-03153-1.
Maher NG, Danaei Mehr H, Cong C, Adegoke NA, Vergara IA, Liu S, Scolyer RA. Weakly supervised deep learning image analysis can differentiate melanoma from naevi on haematoxylin and eosin-stained histopathology slides. J Eur Acad Dermatol Venereol. 2024 Dec;38(12):2250-2258.doi: 10.1111/jdv.20307. Epub 2024 Aug 31.
Lim SY, Lin Y, Lee JH, Pedersen B, Stewart A, Scolyer RA, Long GV, Yang JYH, Rizos H. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors. EBioMedicine. 2024 Sep;107:105308. doi: 10.1016/j.ebiom.2024.105308. Epub 2024 Aug 30.
Martin LK, Guitera P, Long GV, Scolyer RA, Cust AE. Towards evidence-based skin checks. Med J Aust. 2024 Oct 21;221(8):407-409. doi: 10.5694/mja2.52443. Epub 2024 Sep 6.
Ebrahimi A, Gupta R, McDowell L, Magarey MJR, Smith PN, Schulte KM, Perriman DM, Veness M, Porceddu S, Low TH, Fowler A, Clark JR. Determinants of Prognosis in Head and Neck Cutaneous Squamous Cell Carcinoma With Nodal Metastases. JAMA Otolaryngol Head Neck Surg. 2024 Nov 1;150(11):986-994. doi: 10.1001/jamaoto.2024.3103. 
Gide TN, Mao Y, Scolyer RA, Long GV, Wilmott JS. Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma. Clin Cancer Res. 2024 Dec 2;30(23):5270-5280. doi: 10.1158/1078-0432.CCR-24-1109.
Lim SY, da Silva IP, Adegoke NA, Lo SN, Menzies AM, Carlino MS, Scolyer RA, Long GV, Lee JH, Rizos H. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response. Mol Cancer. 2024 Oct 11;23(1):228. doi: 10.1186/s12943-024-02146-0. 
Lai B, Soyer HP, Zhu L, Ferguson PM, O'Brien B, Dodds T, Scolyer RA, Ferrara G, Argenziano G, Bell KJL. Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis: A Scoping Review. JAMA Dermatol. 2024 Dec 1;160(12):1345-1352. doi: 10.1001/jamadermatol.2024.4281. 
Conway K, Edmiston SN, Vondras A, Reiner A, Corcoran DL, Shen R, Parrish EA, Hao H, Lin L, Kenney JM, Ilelaboye G, Kostrzewa CE, Kuan PF, Busam KJ, Lezcano C, Lee TK, Hernando E, Googe PB, Ollila DW, Moschos S, Gorlov I, Amos CI, Ernstoff MS, Cust AE, Wilmott JS, Scolyer RA, Mann GJ, Vergara IA, Ko J, Rees JR, Yan S, Nagore E, Bosenberg M, Rothberg BG, Osman I, Lee JE, Saenger Y, Bogner P, Thompson CL, Gerstenblith M, Holmen SL, Funchain P, Brunsgaard E, Depcik-Smith ND, Luo L, Boyce T, Orlow I, Begg CB, Berwick M, Thomas NE; InterMEL Study Group. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precis Oncol. 2024 Nov;8:e2400375. doi: 10.1200/PO-24-00375. Epub 2024 Nov 7.
Dempsey K, Ho G, Lo SN, McKeown J, Watts CG, Cust AE, Guitera P, Scolyer RA, Thompson JF, Morton RL; MPOC (Melanoma Patterns of Care) Study Group. Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia. JAAD Int. 2024 Oct 18;18:90-100. doi: 10.1016/j.jdin.2024.08.024.
Wu Z, Nickel B, Boroumand F, Elder D, Ferguson PM, Scolyer RA, O'Brien B, Barnhill R, Adamson AS, van Akkooi ACJ, Emery J, Parker L, Low D, Low C, Davies E, Liu S, Lewis S, Spongberg-Ross B, Bell KJ. Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study. BMJ Open. 2024 Dec 20;14(12):e089558. doi: 10.1136/bmjopen-2024-089558. 
Abdus Salam R, Lo S, Varey A, Spillane A, Henderson M, Scolyer R, Mar V, Thompson J, Saw R, van Akkooi A, Stretch J, Hong A, Morton R, Watts C, Smith A, Cust A, et al. Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: a mixed methods study. Surg Oncol Insight. 2024;1(4)
Busam K, Scolyer R. Atlases of Tumor and Non-Tumor Pathology, Series 5, Melanocytic Tumors of the Skin. Washington, DC: American Registry of Pathology; 2024.
Scolyer R. Pathology: the narrative continues. Pathology. 2024;56(3):297